Brief: Tscan Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update

Tscan Therapeutics

10/05/2023 13:47

May 10 (Reuters) - Tscan Therapeutics Inc  TCRX.O :
    * TSCAN THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
    * TSCAN THERAPEUTICS - ENDED Q1 WITH CASH AND CASH
EQUIVALENTS OF
$95.6 MILLION, WHICH COMBINED WITH AMGEN PARTNERSHIP EXTENDS
CASH RUNWAY INTO Q3 2024
    * REVENUE FOR Q1 ENDED MARCH 31, 2023, WAS $6.8 MILLION,
COMPARED
TO $3.0 MILLION FOR Q1 ENDED MARCH 31, 2022
    * QTRLY NET LOSS PER SHARE $0.93
    * Q1 EARNINGS PER SHARE VIEW $-0.74, REVENUE VIEW $4.4
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX48LDMH 
Further company coverage:  TCRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))